drugset / Trial / NCT00544687
Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating enhanced inhibition of tumor necrosis factor- alpha and interferon-gamma release, cytokines that are implicated in the pathogenesis of psoriasis.
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mometasone furoate | Other / unclassified | 0.1 % | Topical |
| Subject | Nortriptyline | Small molecule | 0.05 % | Topical |
| Subject | Nortriptyline | Small molecule | 0.1 % | Topical |
| Comparator | clobetasol-17-propinate | Unknown | 0.05 % | Topical |
Indications
No indication recorded.